150 related articles for article (PubMed ID: 34580638)
1. Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.
Cai TT; Li HQ; Jiang LL; Wang HY; Luo MH; Su XF; Ma JH
Biomed Res Int; 2021; 2021():3361309. PubMed ID: 34580638
[TBL] [Abstract][Full Text] [Related]
2. Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting.
Boye KS; Mody R; Wu J; Lage MJ; Botros FT; Woodward B
Clin Ther; 2018 Aug; 40(8):1396-1407. PubMed ID: 30093131
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
[TBL] [Abstract][Full Text] [Related]
4. The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus.
Akyay OZ; Canturk Z; Selek A; Cetinarslan B; Tarkun İ; Cakmak Y; Baydemir C
Medicine (Baltimore); 2023 Sep; 102(39):e35394. PubMed ID: 37773814
[TBL] [Abstract][Full Text] [Related]
5. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate.
Lorenz M; Lawson F; Owens D; Raccah D; Roy-Duval C; Lehmann A; Perfetti R; Blonde L
Cardiovasc Diabetol; 2017 Jan; 16(1):6. PubMed ID: 28086882
[TBL] [Abstract][Full Text] [Related]
7. Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
Tuttle KR; McKinney TD; Davidson JA; Anglin G; Harper KD; Botros FT
Diabetes Obes Metab; 2017 Mar; 19(3):436-441. PubMed ID: 27766728
[TBL] [Abstract][Full Text] [Related]
8. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
Triplitt C; Solis-Herrera C
Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
[TBL] [Abstract][Full Text] [Related]
9. Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.
Fuechtenbusch M; Aberle J; Heitmann E; Nicolay C; Jung H
Diabetes Obes Metab; 2019 Jun; 21(6):1340-1348. PubMed ID: 30737891
[TBL] [Abstract][Full Text] [Related]
10. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
[TBL] [Abstract][Full Text] [Related]
11. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
Scheen AJ
Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
[TBL] [Abstract][Full Text] [Related]
12. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.
Ishii H; Madin-Warburton M; Strizek A; Thornton-Jones L; Suzuki S
J Med Econ; 2018 May; 21(5):488-496. PubMed ID: 29357718
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis.
Xu J; Yao D; Xia J
J Clin Pharm Ther; 2021 Oct; 46(5):1245-1253. PubMed ID: 33675117
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
Rivera FB; Lumbang GNO; Gaid DRM; Cruz LLA; Magalong JV; Bantayan NRB; Lara-Breitinger KM; Gulati M; Bakris G
Diabetes Obes Metab; 2024 Jun; 26(6):2209-2228. PubMed ID: 38505997
[TBL] [Abstract][Full Text] [Related]
16. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
Edelman SV
J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
[TBL] [Abstract][Full Text] [Related]
17. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Patel D
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
19. Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.
Mody R; Yu M; Nepal B; Konig M; Grabner M
Diabetes Obes Metab; 2021 Jan; 23(1):106-115. PubMed ID: 32945083
[TBL] [Abstract][Full Text] [Related]
20. A Plethora of GLP-1 Agonists: Decisions About What to Use and When.
Samson SL; Garber AJ
Curr Diab Rep; 2016 Dec; 16(12):120. PubMed ID: 27766579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]